Drug Sponsors

Irvine Scientific adds new R&D center of excellence

Wednesday, June 14, 2017

Irvine Scientific, a leader in the development and manufacture of cell culture media, announced the expansion of its Orange County, California, offices and laboratories, with the addition of a 40,000 square foot purpose-built R&D center at 17112 Armstrong Ave, Irvine, California. The growth of the company is in response to increased customer demand for Irvine Scientific’s cell culture and media reagents, and follows the significant expansion of its R&D facilities less than five years ago.

[Read More]

MSD Ireland announces 330 new jobs

Monday, June 5, 2017

MSD, known as Merck in the U.S. and Canada, will create 330 new jobs and invest €280 million over the next three years at two of its Irish manufacturing sites—important links in MSD’s global network of manufacturing plants. MSD maintains headquarters for the company and manufacturing division in the U.S.

[Read More]

Rich Pharma launches clinical site in Thailand

Monday, June 5, 2017

Rich Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, has selected a site and obtained investigator’s interest at Phramongkutklao Hospital in Bangkok, Thailand. Rich has engaged CMIC ASIA-PACIFIC, PTE. LTD. (CMIC) to assist in this project and they have already completed a site selection visit at Phramongkutklao Hospital, and the site has been cleared.

[Read More]

Endocyte to cut workforce 40%

Monday, June 5, 2017

Endocyte, a provider developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, announced updates on clinical development for EC1456, its folate receptor-targeted tubulysin cancer therapy, and EC1169, its prostate-specific membrane antigen targeted (PSMA-targeted) tubulysin prostate cancer therapy.

[Read More]

Eisai, Johns Hopkins extend drug discovery collaboration

Wednesday, May 31, 2017

Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., and  Johns Hopkins University have extended their drug discovery collaboration through an exclusive licensing agreement. The agreement is for a license of compounds identified from collaborative research between Eisai’s Andover Innovative Medicines (AiM) Institute in Andover, Mass., and Johns Hopkins Drug Discovery (JHDD). The compounds were the outcome of research carried out in the laboratory of Professor Barbara Slusher Ph.D., MAS, Professor of Neurology, Neuroscience, Psychiatry, Medicine and Oncology at Johns Hopkins and the Director of JHDD, and is part of a broader ongoing collaborative research arrangement between Eisai and Johns Hopkins that is designed to translate new target discoveries into novel small molecule therapeutics for the development of medicines for neurology and oncology.

[Read More]